see url Here is 2011 Deal Data from IVDnews.com one of the leading data and news sites covering Diagnostics. Contact IVD News for details on all IVD deals for 2011. Recent M&A examples from our focus diagnostic stocks are: Luminex (LMNX) acquisition of EraGen for $34M. Orasure (OSUR)Acquisition of DNA Genotek for $53M. Acquisition of 62% controlling […]
http://akinabridalcouture.com.au/productportfolio/acessories/page/2/ It was a tough week in Life Science Tools and Diagnostics with many crosscurrents: debt ceiling uncertainty, earnings shortfalls, lackluster economic data and European debt crisis. The usual positive buzz from the AACC offered little support. We will provide an updated financial comparison of all stocks in our diagnostic/tools index at the end of Q2 […]
go to site Rayno Life Science Portfolio Recovers Up 1.73%; Jobless Claims Help The thrashing of Illumina (ILMN) yesterday appears to be overdone as the stock is recovering to the $60 area on volume of over 3.5M shares as of mid-day trading.The Tools and Diagnostics sector is still weaker than Biopharma due to focus on sales and earnings […]
Dog Days of Summer Lie Ahead- Q3 Seasonality in Life Sciences is Weak A vicious 16% sell-off in Illumina Inc. (ILMN $58.43) due to revised 2011 guidance and subsequent analysts’ reduced outlook. Concerns about sales growth are a new concern. Revenue for Q2 was $287M a 36.5 %increase over Q2 2010 and an EPS of […]
Weakness in tools such as ILMN ($59.30) down 15% is hurting biotech. Also our mid cap biopharma index is down 2.5% . So the NASDAQ-100 is favored due to the inclusion of AAPL, AMZN, INTC and MSFT etc and larger cap biotech stocks.
Last week we recommended that bulls trade the QQQ rather than pure biotech with ETF’s such as IBB. The strategy was based on the outperformance of biotech compared to tech given that the Q’s also have several large cap biotech stocks. Moreover with IBM and AAPL showing great earnings and price momentum it was more […]
The Rayno Life Science Portfolio was down 1.76% today which in itself is not alarming but given the weekly volatility against a back-drop of macro issues it is time to avoid complacency. Let’s start with the MO players who are those investors with more money than reason but nonetheless have huge gains in selected stocks […]
Note: we will return from vacation this week and focus on companies attending the AACC (American Association of Clinical Chemistry)Meeting in Atlanta this week). Market Down 0.5% as Both Parties Struggle to Come up with Debt Ceiling Plan One half hour into trading the market has cut losses in half. Ideology trumps pragmatism as deficit […]
Life Science Stocks Follow NASDAQ Up: EXAS, MITI, REGN Soar Large healthcare companies report over next two weeks Stocks roared today on IBM earnings last night, debt ceiling negotiation progress with bipartisan Senators,and surge in housing starts. AAPL piled on after hours with a huge beat on sales and earnings and the stock was up […]
With the QQQ you are still Bullish on Biotech We mentioned yesterday that those wanting to be bullish large cap NASDAQ stocks but remain bullish on biotech would be better off with a QQQ position as pure play biotechs are due for a rest. Today the QQQ is up 1.69% compared to biotech ETF’s (IBB,XBI)up […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.